Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation

E Loveman,* K Cooper, J Bryant, JL Colquitt, GK Frampton and A Clegg

Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK

*Corresponding author

Executive summary

Health Technology Assessment 2012; Vol. 16: No. 23
DOI: 10.3310/hta16230
Executive summary

Background

In November 2009, the National Institute for Health and Clinical Excellence (NICE) issued for consultation preliminary recommendations on the use of dasatinib and nilotinib for chronic myeloid leukaemia (CML) in patients whose treatment with imatinib had failed owing to resistance and/or intolerance. This consultation process was informed by a technology assessment report on the clinical effectiveness and cost-effectiveness of dasatinib and nilotinib, prepared by the Peninsula Technology Assessment Group (PenTAG) at the University of Exeter. As a result of the consultation, NICE and the Appraisal Committee identified a need for further information on second-line interventions for people who are resistant to standard-dose imatinib. An updated draft scope was issued by NICE for further consultation, focusing on the use of dasatinib, nilotinib and high-dose imatinib as second-line therapy in patients who are resistant to standard-dose imatinib.

This technology assessment report evaluates the clinical effectiveness and cost-effectiveness of dasatinib, nilotinib and high-dose imatinib, within their licensed indications, for the treatment of people with CML who are resistant to standard-dose imatinib. The present assessment report was commissioned as a supplement to the previous PenTAG assessment report (PenTAG AR), to reflect the inclusion of high-dose imatinib in the updated scope of the consultation.

Objectives

This assessment report has three objectives:

1. to update the existing systematic reviews of clinical effectiveness and cost-effectiveness undertaken in the PenTAG AR, but focusing on people with imatinib-resistant disease only and including high-dose imatinib
2. to critique economic analyses provided by manufacturers in their submissions to NICE
3. to adapt the economic analysis undertaken in the PenTAG AR to reflect the updated scope.

Methods

The three components of the work were conducted systematically following standard procedures, specified a priori in the research protocol. Studies of clinical effectiveness were summarised by narrative review with full tabulation of results.

Systematic review of clinical effectiveness studies

Potentially relevant studies were identified by searching 12 electronic bibliographic databases from inception to January 2011 (such as The Cochrane Library, MEDLINE, EMBASE and MEDLINE In-Process & Other Non-Indexed Citations) and two specialist abstract and conference proceeding resources, and by checking reference lists of articles and contacting experts. Studies were selected for inclusion through a two-stage process. Titles and abstracts were screened for inclusion to identify all of the citations that might meet the inclusion criteria. Full manuscripts of relevant citations were then retrieved and assessed by two reviewers against the following inclusion criteria:
**Population** Patients with imatinib-resistant CML in the chronic, accelerated or blast phase.

**Interventions** Dasatinib, nilotinib or high-dose imatinib.

**Comparators** Dasatinib, nilotinib, high-dose imatinib, hydroxycarbamide, interferon alfa, acute leukaemia-style chemotherapy, allogeneic stem cell transplant, standard-dose imatinib or best supportive care.

**Outcomes** Treatment response rates [including molecular, cytogenetic and haematological responses (HRs)]; time to, and duration of, response; overall survival; event-free survival; progression-free survival; adverse effects of treatment; health-related quality of life; time to treatment failure; costs and cost-effectiveness.

**Study design** Randomised controlled trials (RCTs) and prospective controlled studies were eligible, with single-arm prospective cohort studies being eligible if no higher-level evidence existed; full economic evaluations for the review of cost-effectiveness.

Data from included studies were extracted using a standard data extraction form by one reviewer and checked by a second reviewer. The quality of included studies was appraised by one reviewer and checked by a second reviewer using quality assessment criteria specified in the PenTAG AR. For the systematic review of cost-effectiveness, quality assessment of studies was undertaken using published checklists and NICE guidance specific to the critical appraisal of economic evaluations.

**Evaluation of manufacturers’ submissions and the Peninsula Technology Assessment Group economic model**

Characteristics of the economic evaluations in manufacturer submissions to NICE by Novartis and Bristol-Myers Squibb (BMS) and the economic evaluation conducted by PenTAG were summarised using a standard data collection template. The three economic evaluations were critically appraised by two reviewers using a standard 18-item checklist similar to that used for the quality appraisal of studies in the cost-effectiveness systematic review.

**Southampton Health Technology Assessments Centre analysis**

The PenTAG economic model was updated, taking into account some limitations noted in the two manufacturers’ models and including the interventions dasatinib, nilotinib, and high-dose imatinib and the comparators interferon alfa, standard-dose imatinib, stem cell transplantation and hydroxycarbamide. The analysis focused on those in chronic-phase CML only.

**Results**

**Clinical effectiveness**

Eleven studies met the inclusion criteria. Four of these studies included new data published since the PenTAG AR. These were a published update of a RCT that compared high-dose imatinib against dasatinib, and three single-arm cohort studies that each assessed high-dose imatinib. The RCT had already been identified in the PenTAG AR based on earlier publications. No new studies assessing nilotinib were found. The criteria used to define imatinib failure were slightly different in each of the four studies. All participants had chronic-phase CML, except in one of the single-arm cohort studies that also included very small numbers with accelerated phase and blast crisis (three and four patients, respectively).

The RCT had a number of major limitations (also noted in the PenTAG assessment), which rendered it of limited value as a comparative study and, as such, data for the dasatinib and high-dose imatinib arms are not directly compared in this report. The methodological quality of the single-arm cohort studies was also considered suboptimal. In view of the methodological limitations of the studies included in the systematic review and the heterogeneity in their
reporting, it was considered inappropriate to attempt to combine the results of the studies in a meta-analysis. Instead, relevant new data that were not already included in the PenTAG AR are tabulated and synthesised narratively in this report.

**Summary of benefits and risks: dasatinib**

Only one new publication provided data on the effectiveness of dasatinib. This publication reported new or updated data for the RCT already included in the PenTAG AR. The updated data for the dasatinib arm of the RCT indicate that at 26 months’ follow-up 43.6% of patients had a complete cytogenetic response. At 18 months, 90% of patients maintained a major cytogenetic response. A major molecular response was achieved in 28.7% of patients. The proportion of patients without treatment failure at 24 months was estimated at 59%. Longer follow-up was associated with additional adverse events (AEs: fluid retention, bleeding, infection, upper respiratory tract infection or inflammation), and grades 3–4 fluid retention occurred in 7% of individuals. These results should be interpreted with caution owing to the lack of a comparator and other major limitations of the study.

**Summary of benefits and risks: high-dose imatinib**

Four studies provided data on the effectiveness of high-dose imatinib: one high-dose imatinib arm of the RCT (described above) and three single-arm cohort studies. Data from these four cohorts suggest that, of the patients who received high-dose imatinib, 18–36% achieved a complete cytogenetic response, 33–64% achieved a major cytogenetic response and 56–82% achieved a complete haematological response. One study reported that around three-quarters of individuals maintained their major cytogenetic response at 18 months. Event-free survival of ≥ 2 years occurred in 34% of patients in one study and progression-free survival in 65–87% in two studies. Only two studies reported overall survival; they reported that 85–93% of patients would be expected to survive ≥ 2 years. Grades 3–4 haematological AEs occurred in up to 40% of patients. Non-haematological events included anorexia, diarrhoea, fatigue, muscle spasms, musculoskeletal pain, superficial oedema and rash. Grades 3–4 non-haematological AEs did not occur in more than 5% of patients. Between 0% and 20% of patients discontinued high-dose imatinib owing to AEs. These results should be interpreted with caution owing to the lack of a comparator and other study limitations.

**Economic analysis**

The systematic review identified one cost-effectiveness study that compared dasatinib with high-dose imatinib. The results showed that chronic-phase CML patients who are resistant to standard-dose imatinib gain 0.62 QALYs (quality-adjusted life-years) when treated with dasatinib compared with high-dose imatinib, and the incremental societal cost would be €4250 during the lifetime period or €6880 per QALY gained. It is unclear how generalisable these results are to the UK NHS, as the study was conducted in Sweden and takes a societal perspective.

The Novartis submission compared nilotinib with high-dose imatinib and also had an exploratory analysis versus stem cell transplantation/hydroxycarbamide. The results showed that nilotinib dominates high-dose imatinib (i.e. is more effective and less costly). The exploratory analysis gives an incremental cost-effectiveness ratio (ICER) of about £44,000 per QALY gained for nilotinib versus stem cell transplantation/hydroxycarbamide.

The BMS submission compared dasatinib, nilotinib and high-dose imatinib with standard-dose imatinib, stem cell transplantation, hydroxycarbamide, interferon alfa, acute leukaemia-style chemotherapy and best supportive care. The results showed that dasatinib dominates high-dose imatinib, nilotinib and stem cell transplantation.
There are two main differences between the industry models: in the BMS model, patients are treated until progression, which incurs greater costs; in the Novartis model the assumed third-line treatment is stem cell transplantation/hydroxyurea, which has associated high mortality and reduced overall survival. These key assumptions drive the differences between the models.

The PenTAG economic evaluation compared dasatinib and nilotinib with high-dose imatinib. Further analyses comparing these three treatments to interferon alfa were reported in an appendix. The results showed that nilotinib dominates high-dose imatinib and the ICER for nilotinib versus interferon alfa is about £44,600. The ICER for dasatinib versus nilotinib is over £277,000. Concerns relate to the fact that there is no link between overall survival and progression-free survival, as overall survival is based on major cytogenetic response but progression-free survival is not, and also the estimate for survival on interferon alfa does not fit with clinical advice.

Southampton Health Technology Assessments Centre analysis

The Southampton Health Technology Assessments Centre conducted analyses for the interventions dasatinib, nilotinib and high-dose imatinib and the comparators interferon alfa, standard-dose imatinib, stem cell transplantation and hydroxyurea. Owing to large uncertainties in the parameter inputs to the model, these analyses should be treated as exploratory. The results suggest that the three interventions, dasatinib, nilotinib and high-dose imatinib, have similar costs and effectiveness. Nilotinib and dasatinib are slightly more cost-effective than high-dose imatinib because of slightly lower costs and better effectiveness. Dasatinib, nilotinib and high-dose imatinib are all cost-effective when compared with hydroxyurea, for a willingness to pay (WTP) of about £30,000 per QALY. It is not possible to derive firm conclusions about the relative cost-effectiveness of the three interventions owing to great uncertainty around data inputs.

The uncertainty around the model results were explored using deterministic sensitivity analyses, threshold analyses and probabilistic sensitivity analyses. Deterministic sensitivity analyses showed that changes in overall survival for hydroxyurea and changes in treatment efficacy of the interventions had little impact on results. A probabilistic sensitivity analysis was run comparing the interventions dasatinib, nilotinib, high-dose imatinib and hydroxyurea. For a WTP threshold of £20,000 per QALY, hydroxyurea is the most cost-effective treatment. For a WTP threshold of £30,000 per QALY, nilotinib, dasatinib, hydroxyurea and high-dose imatinib have probabilities of being cost-effective of 60%, 28%, 12% and 0%, respectively.

Limitations

There are a number of important concerns that have a bearing on the outcome of this update report. These predominantly centre around the paucity of good-quality evidence, which provides uncertain data for the key outcomes of relevance to the scope.

Discussion and conclusions

This report is a supplement to the PenTAG AR and such the results reported herein must be considered in conjunction with the PenTAG AR.

Data suggest that dasatinib, nilotinib and high-dose imatinib appear to be efficacious in terms of obtaining cytogenetic and HRs in the imatinib-resistant population. However, there remains
an absence of evidence with which to assess the relative effectiveness of dasatinib, nilotinib and high-dose imatinib in imatinib-resistant CML, and the impact on long-term outcomes is difficult to conclude.

The uncertainties in the data mean that our exploratory cost-effectiveness analysis should be treated with caution. Although we have attempted to address the key areas of uncertainty in this update analysis, we do not feel able to make firm conclusions regarding the use of these technologies in patients with chronic-phase CML. In addition, owing to the paucity of data, we have not been able to model these technologies for accelerated phase or patients with blast-crisis-phase CML.

The implications for future research are not altered from the recommendation that PenTAG made, identifying the need for a three-way, randomised clinical trial of dasatinib, nilotinib and high-dose imatinib.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

**Publication**

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke
Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 09/90/01. The protocol was agreed in July 2010. The assessment report began editorial review in July 2011 and was accepted for publication in July 2011. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Tom Marshall, Professor John Powell, Dr Rob Rimensma and Professor Ken Stein
Associate Editor: Dr Peter Davidson
Editorial Contact: edit@southampton.ac.uk
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
ISSN 2046-4932 (DVD)

© Queen’s Printer and Controller of HMSO 2012. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/).

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.
Printed on acid-free paper in the UK by Charlesworth Press.